关于儿童罕见疾病的模型信息化药物开发方法的最先进技术
Rajesh Krishna1, Amitava Mitra2, Matthew L Zierhut1
1Certara Scientific Innovation, Certara USA, Inc, Radnor, Pennsylvania, USA.
CPT: pharmacometrics & systems pharmacology
|July 23, 2025
概括
模型信息化药物开发 (MIDD) 使用定量方法来克服开发用于儿科罕见病药物的挑战. 这些方法优化了剂量,支持数据推断,并使儿童能够进行高效,道德的临床试验.
科学领域:
- 药量计学和定量药理学
- 儿科药物开发 儿科药物开发
- 罕见疾病治疗方法 罕见疾病治疗方法
背景情况:
- 儿科罕见病对药物开发构成重大障碍,包括患者数量少和自然史数据有限.
- 传统的临床试验设计在儿科罕见病研究中面临道德和后勤挑战.
- 模型信息化药物开发 (MIDD) 提供了一个定量框架来解决这些复杂性.
研究的目的:
- 审查当前的儿童罕见病治疗方法的模型信息化药物开发 (MIDD).
- 突出MIDD如何在儿科药物开发中促进剂量优化和数据推断.
- 讨论MIDD在为罕见儿科疾病提供高效和道德的临床试验策略方面的作用.
主要方法:
- 审查最先进的MIDD方法,包括人口药理动力学/药理动力学 (PK/PD) 建模.
- 生理学基础的药理动力学 (PBPK) 建模和疾病进展建模的应用.
- 整合贝叶斯试验设计和现实世界的数据,以加强决策.
主要成果:
- 对于儿科罕见病治疗,MIDD方法有效支持剂量优化.
- 从成年人或其他儿科患者群体的数据进行推断是MIDD所促进的.
- 案例研究表明,在儿童罕见病提交中,MIDD的监管接受度越来越高.
结论:
- MIDD是加速为患有罕见疾病的儿童开发安全有效治疗的关键范式.
- 技术和监管方面的进步正在推动MIDD应用在这个领域的扩展.
- 未来有机会进一步增强MIDD对儿科罕见病疗法的影响.
相关概念视频
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
228
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
228
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Pharmacokinetic Models: Overview
1.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.2K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
128
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
128


